A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
NCT07492680 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 260
Last updated 2026-03-25
Summary
This is an open-label, multicenter Phase 2 study evaluating BMS-986504 in participants with advanced and/or metastatic solid tumors that have MTAP deletion. The study includes a monotherapy component and a combination component in which BMS-986504 is given with other anti-cancer agents. The trial will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of BMS-986504 alone and in combination regimens.
Conditions
Interventions
- DRUG
-
BMS-986504
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Nivolumab + Relatlimab FDC
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Pumitamig
Specified dose on specified days
- DRUG
-
Pemetrexed
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
- DRUG
-
Specified dose on specified days
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Bristol-Myers Squibb · Bristol-Myers Squibb
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-07-17
- Primary Completion
- 2032-05-20
- Completion
- 2032-05-20
- FDA Drug
- Yes
Countries
- United States
- Belgium
- Canada
- China
- France
- Germany
- Hong Kong
- Ireland
- Italy
- Japan
- Norway
- South Korea
- Spain
Study Locations
More Related Trials
-
Paclitaxel Polymeric Micelles and Carboplatin in Combination With Iparomilimab and Tuvonralimab Neoadjuvant Therapy for Triple-negative Breast Cancer
NCT06910072 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
NCT01881230 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC
NCT03567720 ·Status: UNKNOWN ·Phase: PHASE2
-
BMS-599626 in Treating Patients With Metastatic Solid Tumors
NCT00093730 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
NCT05120960 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
NCT05010031 ·Status: RECRUITING ·Phase: PHASE2
-
Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment
NCT07467330 ·Status: RECRUITING ·Phase: PHASE3
-
Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
NCT02734290 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
NCT02308020 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT03424005 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
NCT00153907 ·Status: COMPLETED ·Phase: PHASE1
-
Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer
NCT03121352 ·Status: COMPLETED ·Phase: PHASE2
-
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
NCT06492759 ·Status: RECRUITING ·Phase: PHASE2
-
Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
NCT03130439 ·Status: TERMINATED ·Phase: PHASE2
-
Phase II Study of Tetrathiomolybdate (TM) in Patients With Breast Cancer
NCT00195091 ·Status: TERMINATED ·Phase: PHASE2
-
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
NCT00616967 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
NCT03316794 ·Status: TERMINATED ·Phase: PHASE1
-
Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency
NCT05461690 ·Status: UNKNOWN ·Phase: PHASE2
-
BMS-247550 in Treating Women With Metastatic Breast Cancer
NCT00020904 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer
NCT06246968 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)
NCT06975644 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer
NCT06685796 ·Status: RECRUITING ·Phase: PHASE2
-
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
NCT00068588 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
NCT03775525 ·Status: UNKNOWN ·Phase: PHASE1
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT03971409 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2